OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Borgen Discusses the Patents on BRCA1 and BRCA2

April 8th 2013

Patrick Borgen, MD, chair, Department of Surgery, director, Maimonides Breast Cancer Center, discusses the patents on BRCA1 and BRCA2.

Dr. Cheson on the Diagnosis of Follicular Lymphoma

April 8th 2013

Bruce D. Cheson, MD, Professor of Medicine, Head of Hematology, Director of Hematology Research, Georgetown Lombardi Comprehensive Cancer Center, discusses the diagnosis of patients with follicular lymphoma.

Dr. Crawford on Sipuleucel-T in Advanced Prostate Cancer

April 5th 2013

E. David Crawford, MD, from the University of Colorado, Anschutz Medical Campus, discusses the effectiveness of the immunotherapy sipuleucel-T as a treatment for men with advanced prostate cancer.

Dr. Carey on Everolimus in Metastatic Breast Cancer

April 5th 2013

Lisa A. Carey, MD, Professor of Medicine, University of North Carolina at Chapel Hill, discusses the use of everolimus in the metastatic and adjuvant settings of breast cancer.

Dr. Berenson Discusses New Potential Targets in Myeloma

April 4th 2013

James R. Berenson, MD, Medical and Scientific Director, Institute for Myeloma & Bone Cancer Research, Chief Executive Officer, Oncotherapeutics, comments on new potential targets in myeloma.

Dr. Sledge Discusses Lasting Issues in Breast Cancer

April 4th 2013

George W. Sledge, Jr, MD, Chief, Division of Oncology, Professor of Medicine, Stanford University School of Medicine, discusses the lasting issues in the treatment of breast cancer.

Dr. Silver on Hydroxyurea and Interferon in MPNs

April 3rd 2013

Richard T. Silver, MD, Professor of Medicine, Director, Leukemia and Myleoproliferative Center, New York Presbyterian-Weill Cornell Medical Center, discusses the use hydroxyurea and interferons in myeloproliferative neoplasms.

Dr. Muss on the Treatment Team for Older Cancer Patients

April 3rd 2013

Hyman B. Muss, MD, Professor of Medicine, Director of Geriatric Oncology, Division of Hematology and Oncology, Lineberger Comprehensive Cancer Center at the University of North Carolina at Chapel Hill School of Medicine, discusses the need for a team environment when treating an older patient.

Dr. Pinter-Brown on Treatment Expectations in CTCL

April 2nd 2013

Lauren Pinter-Brown, MD, Clinical Professor, Department of Medicine, Hematology-Oncology, University of California, Los Angeles, discusses physician and patient expectations when treating cutaneous T-cell lymphoma.

Dr. Andre on Research in Metastatic Breast Cancer

April 2nd 2013

Fabrice Andre, MD, PhD, Research Director, Head of INSERM Unit U981, Institut National des Sciences et de la Recherche MÃ©dicale, Associate Professor, Department of Medical Oncology, Institut Gustave Roussy, Villejuif, France, discusses upcoming research in metastatic breast cancer.

Dr. Jennifer Brown on Mutations and Targets in CLL

April 1st 2013

Jennifer Brown, MD, PhD, Director, Chronic Lymphocytic Leukemia Center, Dana-Farber Cancer Institute, Assistant Professor of Medicine, Harvard Medical School, discusses targeted therapies and mutations in chronic lymphocytic leukemia.

Dr. Dreicer on an Alternate Sunitinib Schedule in mRCC

April 1st 2013

Robert Dreicer, MD, MS, from the Cleveland Clinic in Ohio, discusses a 2-weeks-on and 1-week-off (2/1) schedule of sunitinib for patients with metastatic renal cell carcinoma.

Dr. Baselga Discusses PIK3CA Inhibitors in Breast Cancer

March 29th 2013

JosÃ© Baselga, MD, PhD, Physician-in-Chief, Memorial Sloan-Kettering Cancer Center, discusses treatment with PIK3CA inhibitors in patients with breast cancer.

Dr. Landgren Discusses Risk and Treatment in Myeloma

March 28th 2013

Ola Landgren, MD, PhD, Head, Multiple Myeloma Section, National Cancer Institute, discusses the relationship between risk and treatment in patients with multiple myeloma.

Emanuel Petricoin Discusses Tumor Heterogeneity

March 28th 2013

Emanuel F. Petricoin III, PhD, Co-Director, Center for Applied Proteomics & Molecular Medicine, Professor of Life Sciences, George Mason University, discusses tumor heterogeneity in patients with breast cancer.

Dr. Advani on EPOCH-R in B Cell Lymphoma

March 27th 2013

Ranjana Advani, MD, Professor of Medicine and Oncology, Stanford University, details the difference between EPOCH-R and R-CHOP chemotherapy.

Dr. Sandler on the Unique Characteristics of Radium-223

March 27th 2013

Howard M. Sandler, MD, the Chair of Radiation Oncology at Cedars-Sinai Medical Center, discusses radium-223, a novel alpha radiation emitting agent under evaluation by the FDA for patients with bone metastases from advanced castration-resistant prostate cancer (CRPC).

Dr. Piccart on Metagene Prognostic Signatures

March 27th 2013

Martine Piccart, MD, PhD, director of medicine at the Jules Bordet Institute in Brussels, Belgium, discusses the development of metagene prognostic signatures for patients with breast cancer.

Dr. Mark Pegram Discusses Earlier Treatment With T-DM1

March 26th 2013

Mark D. Pegram, MD, from the Stanford Cancer Institute, describes research into the antibody-drug conjugate T-DM1, following its FDA approval in February as a treatment for HER2-positive metastatic breast cancer.

Dr. Wetzler Discusses the Use of Arsenic Trioxide in APL

March 26th 2013

Meir Wetzler, MD, Chief, Leukemia Section, Department of Medicine, Roswell Park Cancer Institute, discusses a study presented at the 2012 American Society of Hematology Meeting analyzing arsenic trioxide in acute promyelocytic leukemia.